FDA sends two more CBD warning letters
CBDIndustrial Hemp NewsMarijuana Laws, Regulations, & Politics March 22, 2021 MJ Shareholders 0
Two companies, one in California and the other in Michigan, are the latest to receive warning letters about CBD from the U.S. Food and Drug Administration.
The warnings posted Monday accuse BioLyte Laboratories of Grand Rapids, Michigan, and Honest Globe of Santa Ana, California, of selling CBD pain relief products over the counter, a violation of federal law.
“No CBD-containing drug has met applicable FDA requirements to be legally marketed for nonprescription use,” the FDA told Honest Globe.
BioLyte was warned that CBD can’t be sold even as an inactive ingredient. The agency noted that BioLyte’s label mentioned “pain relief cream with rejuvenating CBD.”
The companies must respond within 15 days.
The FDA’s latest CBD warnings come two months after the agency withdrew suggested CBD regulations that were awaiting White House review.
President Joe Biden has yet to name a permanent FDA commissioner; Dr. Janet Woodcock has been serving as acting commissioner since Jan. 20.
MJ Shareholders
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers
No comments so far.
Be first to leave comment below.